BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

Core Viewpoint - BioXcel Therapeutics, Inc. reported a quarterly loss of $0.32 per share, which was better than the Zacks Consensus Estimate of a loss of$ 0.50, and a significant improvement from a loss of $1.72 per share a year ago, indicating a 36% earnings surprise [1] Financial Performance - The company posted revenues of$ 0.21 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 82.17%, and a decline from $0.34 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - BioXcel Therapeutics shares have lost about 79% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$ 0.49 on revenues of $1.24 million, and for the current fiscal year, it is -$ 1.97 on revenues of $4.12 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which could impact future stock movements [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]